These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma. Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669 [TBL] [Abstract][Full Text] [Related]
6. Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines. Marampon F; Di Nisio V; Pietrantoni I; Petragnano F; Fasciani I; Scicchitano BM; Ciccarelli C; Gravina GL; Festuccia C; Del Fattore A; Tombolini M; De Felice F; Musio D; Cecconi S; Tini P; Maddalo M; Codenotti S; Fanzani A; Polimeni A; Maggio R; Tombolini V Cancer Lett; 2019 Oct; 461():90-101. PubMed ID: 31325529 [TBL] [Abstract][Full Text] [Related]
7. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells. De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362 [TBL] [Abstract][Full Text] [Related]
8. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416 [TBL] [Abstract][Full Text] [Related]
9. The botanical drug PBI-05204, a supercritical CO Vaccaro S; Rossetti A; Porrazzo A; Camero S; Cassandri M; Pomella S; Tomaciello M; Macioce G; Pedini F; Barillari G; Marchese C; Rota R; Cenci G; Tombolini M; Newman RA; Yang P; Codenotti S; Fanzani A; Megiorni F; Festuccia C; Minniti G; Gravina GL; Vulcano F; Milazzo L; Marampon F Front Pharmacol; 2022; 13():1071176. PubMed ID: 36532747 [TBL] [Abstract][Full Text] [Related]
10. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
11. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma. Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014 [TBL] [Abstract][Full Text] [Related]
12. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies. Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109 [TBL] [Abstract][Full Text] [Related]
15. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma. Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375 [TBL] [Abstract][Full Text] [Related]
16. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma. Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678 [TBL] [Abstract][Full Text] [Related]
17. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors. de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386 [TBL] [Abstract][Full Text] [Related]
18. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA. Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396 [TBL] [Abstract][Full Text] [Related]
19. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma. Laubscher D; Gryder BE; Sunkel BD; Andresson T; Wachtel M; Das S; Roschitzki B; Wolski W; Wu XS; Chou HC; Song YK; Wang C; Wei JS; Wang M; Wen X; Ngo QA; Marques JG; Vakoc CR; Schäfer BW; Stanton BZ; Khan J Nat Commun; 2021 Nov; 12(1):6924. PubMed ID: 34836971 [TBL] [Abstract][Full Text] [Related]
20. The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth. Gualtieri A; Bianconi V; Renzini A; Pieroni L; Licursi V; Mozzetta C Cell Rep; 2022 Aug; 40(9):111267. PubMed ID: 36044855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]